[go: up one dir, main page]

CR20190550A - Anticuerpos que se unen específicamente a pd-1 y métodos de uso - Google Patents

Anticuerpos que se unen específicamente a pd-1 y métodos de uso

Info

Publication number
CR20190550A
CR20190550A CR20190550A CR20190550A CR20190550A CR 20190550 A CR20190550 A CR 20190550A CR 20190550 A CR20190550 A CR 20190550A CR 20190550 A CR20190550 A CR 20190550A CR 20190550 A CR20190550 A CR 20190550A
Authority
CR
Costa Rica
Prior art keywords
antibodies
methods
specifically bind
fragments
inflammatory
Prior art date
Application number
CR20190550A
Other languages
English (en)
Inventor
Damon Hamel
Shannon Hitchcock
Jinquan Luo
Karen Duffy
Suzanne Cole
Yanxia Guo
Yevgeniya Orlovsky
Qiang Chen
Deepti Wilkinson
Debra Gardner
Ann Lacombe
Melissa Swiecki
Pejman Soroosh
Ravi Malaviya
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CR20190550A publication Critical patent/CR20190550A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Los anticuerpos que se unen específicamente a PD-1 o fragmentos de unión al antígeno de estos, los polinucleótidos que codifican los anticuerpos o fragmentos, y los métodos de fabricación y uso de los anteriores son útiles en el tratamiento de trastornos inflamatorios o inmunitarios.
CR20190550A 2017-06-05 2018-06-04 Anticuerpos que se unen específicamente a pd-1 y métodos de uso CR20190550A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762515188P 2017-06-05 2017-06-05
US201862648114P 2018-03-26 2018-03-26
US201862673185P 2018-05-18 2018-05-18
PCT/US2018/035843 WO2018226580A2 (en) 2017-06-05 2018-06-04 Antibodies that specifically bind pd-1 and methods of use

Publications (1)

Publication Number Publication Date
CR20190550A true CR20190550A (es) 2020-04-05

Family

ID=64562613

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190550A CR20190550A (es) 2017-06-05 2018-06-04 Anticuerpos que se unen específicamente a pd-1 y métodos de uso

Country Status (24)

Country Link
US (3) US10995149B2 (es)
EP (1) EP3634995A4 (es)
JP (1) JP7235733B2 (es)
KR (1) KR102692379B1 (es)
CN (1) CN110997712B (es)
AU (1) AU2018282094B2 (es)
BR (1) BR112019025574A2 (es)
CA (1) CA3065516A1 (es)
CL (1) CL2019003520A1 (es)
CO (1) CO2019013935A2 (es)
CR (1) CR20190550A (es)
EC (1) ECSP19086810A (es)
IL (1) IL271009B2 (es)
MA (1) MA52459A (es)
MX (1) MX2019014577A (es)
MY (1) MY199715A (es)
NI (1) NI201900123A (es)
PE (1) PE20200294A1 (es)
PH (1) PH12019502755A1 (es)
TW (1) TWI806873B (es)
UA (1) UA128035C2 (es)
UY (1) UY37761A (es)
WO (1) WO2018226580A2 (es)
ZA (1) ZA202000051B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3244313A1 (en) * 2017-06-02 2025-06-13 Bayer Healthcare Llc Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
AR114127A1 (es) 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
CN114957475B (zh) * 2018-09-26 2023-06-20 福州拓新天成生物科技有限公司 抗b7-h3的单克隆抗体及其在细胞治疗中的应用
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
KR20210125511A (ko) * 2019-02-05 2021-10-18 씨젠 인크. 항-cd228 항체 및 항체-약물 컨쥬게이트
US12466862B2 (en) * 2019-06-04 2025-11-11 Arizona Board Of Regents On Behalf Of Arizona State University Plant-produced mABs against chikungunya virus with enhanced effector function and efficacy
TWI809286B (zh) * 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
CN114174343A (zh) * 2019-07-30 2022-03-11 小野药品工业株式会社 双特异性抗体
EP4011918A4 (en) 2019-08-08 2023-08-23 ONO Pharmaceutical Co., Ltd. DUAL SPECIFIC PROTEIN
KR20220143869A (ko) * 2020-02-21 2022-10-25 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-il-2 항체, 이의 항원-결합 단편 및 이의 의학적 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
PL4157876T3 (pl) 2020-05-26 2025-02-03 Boehringer Ingelheim International Gmbh Przeciwciała anty-pd-1
WO2022156773A1 (en) * 2021-01-21 2022-07-28 Biocytogen Pharmaceuticals (Beijing) Co., Ltd Protein complexes targeting il12 pathway
JPWO2022239820A1 (es) * 2021-05-13 2022-11-17
KR20240049265A (ko) * 2021-06-18 2024-04-16 테리니 바이오, 인코포레이티드 인간 피브린 또는 피브리노겐 γC 도메인에 결합하는 항체 및 사용 방법
WO2023070100A1 (en) * 2021-10-21 2023-04-27 Seismic Therapeutic, Inc. Dual targeted immune regulating compositions
JP2024539457A (ja) 2021-11-19 2024-10-28 ミロバイオ・リミテッド 操作されたｐｄ－１抗体及びその使用
CN118984837A (zh) * 2022-01-28 2024-11-19 乔治穆内公司 作为pd-1激动剂的程序性细胞死亡蛋白1的抗体
CN119630701A (zh) * 2022-07-06 2025-03-14 圣塔安娜生物股份有限公司 用于治疗自身免疫性、过敏性和炎症性疾病的方法和组合物
WO2024076993A2 (en) * 2022-10-03 2024-04-11 Therini Bio, Inc. Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use
AU2023356930A1 (en) * 2022-10-03 2025-05-15 Therini Bio, Inc. Multi-specific antigen binding proteins which bind human fibrin or fibrinogen ?c domain and vascular endothelial growth factor and methods of use
CN120303301A (zh) * 2022-10-11 2025-07-11 艾比欧公司 表皮生长因子受体变体iii抗体
AU2023367781A1 (en) 2022-10-25 2025-06-05 Seismic Therapeutic, Inc. VARIANT IgG FC POLYPEPTIDES AND USES THEREOF
CN116854820B (zh) * 2023-06-26 2024-02-06 华中科技大学同济医学院附属协和医院 Pd-1非阻断性清除抗体及其用途
WO2025151607A1 (en) * 2024-01-10 2025-07-17 Santa Ana Bio, Inc. Methods and compositions for treating autoimmune, allergic and inflammatory diseases
WO2026008664A1 (en) 2024-07-01 2026-01-08 Vib Vzw Allosteric modulators of inhibitory immune receptor complexes
CN120040594B (zh) * 2025-02-21 2025-09-23 四川大学 一种靶向flt3基因编辑通用型car-t细胞的制备方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
ATE319745T1 (de) 1997-05-21 2006-03-15 Biovation Ltd Verfahren zur herstellung von nicht-immunogenen proteinen
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1916303B1 (en) 2000-11-30 2013-02-27 Medarex, Inc. Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
CA2710373A1 (en) 2007-12-19 2009-07-09 Ping Tsui Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2736829C (en) 2008-09-12 2018-02-27 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
EP2342228B1 (en) 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
WO2010045340A1 (en) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US8993731B2 (en) 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
ES2989108T3 (es) 2010-04-20 2024-11-25 Genmab As Proteínas que contienen FC de anticuerpos heterodiméricos y métodos para producir las mismas
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
AU2011333738A1 (en) 2010-11-24 2013-07-11 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
ES2690047T3 (es) 2013-03-15 2018-11-19 Janssen Biotech, Inc. Procedimientos de fabricación para controlar la lisina C-terminal, la galactosa y el contenido de ácido siálico en proteínas recombinantes
CN104558177B (zh) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
CA2932476A1 (en) 2013-12-12 2015-06-18 Stemcentrx, Inc. Novel anti-dpep3 antibodies and methods of use
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
ES2915101T3 (es) * 2014-03-27 2022-06-20 Bird Rock Bio Inc Anticuerpos que se unen al receptor cannabinoide 1 (CB1) humano
SG11201700672YA (en) * 2014-08-05 2017-02-27 MabQuest SA Immunological reagents binding to pd-1
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CA2971734C (en) 2014-12-22 2025-11-18 Enumeral Biomedical Holdings Inc Anti-pd-1 antibodies
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
SG10201906059VA (en) 2015-07-30 2019-08-27 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
DK3334763T3 (da) 2015-08-11 2024-10-07 Wuxi Biologics Ireland Ltd Nye anti-PD-1-antistoffer
WO2017040790A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
WO2017058859A1 (en) * 2015-09-29 2017-04-06 Celgene Corporation Pd-1 binding proteins and methods of use thereof
LT3370768T (lt) 2015-11-03 2022-05-25 Janssen Biotech, Inc. Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
RU2656181C1 (ru) 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
MX2019002946A (es) 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.
CN109952317A (zh) 2016-09-19 2019-06-28 细胞基因公司 使用pd-1结合蛋白治疗免疫病症的方法
CN110799213A (zh) 2017-06-01 2020-02-14 康姆普根有限公司 三联组合抗体疗法
AU2018330180B2 (en) 2017-09-07 2025-07-17 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
AR114127A1 (es) 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos

Also Published As

Publication number Publication date
TW201906863A (zh) 2019-02-16
JP2020522278A (ja) 2020-07-30
MX2019014577A (es) 2020-07-29
CN110997712A (zh) 2020-04-10
EP3634995A2 (en) 2020-04-15
JP7235733B2 (ja) 2023-03-08
IL271009B1 (en) 2025-06-01
UA128035C2 (uk) 2024-03-20
IL271009B2 (en) 2025-10-01
US11746161B2 (en) 2023-09-05
MA52459A (fr) 2021-03-10
US20230340155A1 (en) 2023-10-26
EP3634995A4 (en) 2021-06-09
CA3065516A1 (en) 2018-12-13
CO2019013935A2 (es) 2020-01-17
MY199715A (en) 2023-11-20
UY37761A (es) 2019-01-02
WO2018226580A2 (en) 2018-12-13
NI201900123A (es) 2020-12-01
WO2018226580A3 (en) 2019-01-31
US20180355061A1 (en) 2018-12-13
AU2018282094B2 (en) 2024-06-27
US20210102000A1 (en) 2021-04-08
ZA202000051B (en) 2021-07-28
PH12019502755A1 (en) 2020-06-08
TWI806873B (zh) 2023-07-01
AU2018282094A1 (en) 2019-12-12
ECSP19086810A (es) 2020-02-28
US10995149B2 (en) 2021-05-04
CN110997712B (zh) 2024-03-19
KR102692379B1 (ko) 2024-08-05
PE20200294A1 (es) 2020-02-05
KR20200014414A (ko) 2020-02-10
CL2019003520A1 (es) 2020-05-08
BR112019025574A2 (pt) 2020-06-23
IL271009A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
CR20190550A (es) Anticuerpos que se unen específicamente a pd-1 y métodos de uso
SA520420631B1 (ar) الأجسام المضادة لـ cd3 واستخداماتها
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
CY1125267T1 (el) Antiσωmata eiδiκως σynδeonta pd-1 kai xphσeiς aytωn
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
MX394121B (es) Anticuerpos que se unen a cd39 y sus usos
SI3638698T1 (sl) Protitelesa proti-TMPRSS2 in delci, ki vežejo antigen
MX2020000960A (es) Anticuerpos anti-tigit.
EA202091540A1 (ru) Антитела к lilrb2
CY1121893T1 (el) Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων
IL259832B (en) Monoclonal antibodies, or fragments thereof, that bind hiv gp120 and polynucleotides encoding them
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
JOP20190292A1 (ar) استخدام الأجسام المضادة لربط il-1? في علاج السرطان
UY37083A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
BR112018006251A2 (pt) anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
CU20170169A7 (es) Anticuerpos de factor xi
MX375032B (es) Proteínas de unión y métodos para utilizarlas.
MX2017001959A (es) Anticuerpos especificos para mmp9.
IL262404A (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
MX389103B (es) Anticuerpos contra ticagrelor y métodos de uso.
AR116101A1 (es) Proteína de unión al antígeno anti-steap1
EA201992885A1 (ru) Антитела, специфически связывающиеся с pd-1, и способы их применения